Conatus Pharmaceuticals to Report First Quarter 2017 Financial Results
April 27 2017 - 4:05PM
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it
will report financial results for the first quarter ended March 31,
2017, after the market close on Thursday, May 4, 2017. Conatus will
host a conference call and audio webcast at 4:30 p.m. Eastern Time
on Thursday, May 4, 2017, to discuss the financial results and
provide a corporate update.
To access the conference call, please dial
877-312-5857 (domestic) or 970-315-0455 (international) at least
five minutes prior to the start time and refer to conference ID
10334037. A live and archived audio webcast of the call will also
be available in the Investors section of the Conatus website at
www.conatuspharma.com.
About Conatus
PharmaceuticalsConatus is a biotechnology company focused
on the development and commercialization of novel medicines to
treat liver disease. Conatus is developing its lead compound,
emricasan, for the treatment of patients with chronic liver
disease. Emricasan is designed to reduce the activity of enzymes
that mediate inflammation and apoptosis. Conatus believes that by
reducing the activity of these enzymes, emricasan has the potential
to interrupt the disease progression across the spectrum of liver
disease. For additional information, please visit
www.conatuspharma.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical facts
contained in this press release are forward-looking statements,
including statements regarding emricasan’s potential to interrupt
the disease progression across the spectrum of liver
disease. In some cases, you can identify forward-looking
statements by terms such as “may,” “will,” “should,” “expect,”
“plan,” “anticipate,” “could,” “intend,” “target,” “project,”
“contemplates,” “believes,” “estimates,” “predicts,” “potential” or
“continue” or the negative of these terms or other similar
expressions. These forward-looking statements speak only as of
the date of this press release and are subject to a number of
risks, uncertainties and assumptions, including those risks
described in the company’s prior press releases and in the periodic
reports it files with the Securities and Exchange
Commission. The events and circumstances reflected in the
company’s forward-looking statements may not be achieved or occur
and actual results could differ materially from those projected in
the forward-looking statements. Except as required by applicable
law, the company does not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances or
otherwise.
Alan Engbring
Conatus Pharmaceuticals Inc.
(858) 376-2637
aengbring@conatuspharma.com
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Sep 2023 to Sep 2024